Welcome to our dedicated page for Immunic news (Ticker: IMUX), a resource for investors and traders seeking the latest updates and insights on Immunic stock.
Immunic, Inc. (Nasdaq: IMUX) generates frequent news as a late-stage biotechnology company advancing oral small molecule therapies for neurologic, gastrointestinal, and other chronic inflammatory and autoimmune diseases. Most company updates center on its lead asset, vidofludimus calcium (IMU-838), and the progression of multiple sclerosis clinical programs, as well as emerging data from its gastrointestinal pipeline candidates.
News items commonly highlight clinical trial milestones, such as completion of enrollment in the twin phase 3 ENSURE trials in relapsing multiple sclerosis, new long-term open-label extension data from the phase 2 EMPhASIS trial in relapsing-remitting multiple sclerosis, and detailed results from the phase 2 CALLIPER trial in progressive multiple sclerosis. Releases also cover scientific presentations at major congresses, including oral and poster presentations at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), neuroimmunology meetings, and gastroenterology conferences.
Investors following IMUX news will also see intellectual property developments, such as Notices of Allowance from the U.S. Patent and Trademark Office for patents protecting vidofludimus calcium dose strengths and other aspects of its use in multiple sclerosis. Corporate updates regularly include financing announcements, quarterly financial results, and commentary on cash resources to support ongoing and planned studies.
For Immunic’s broader pipeline, news coverage includes analyses of IMU-856 in celiac disease and other gastrointestinal disorders, preclinical and early clinical findings related to intestinal barrier function and gut hormone levels, and the status of IMU-381 in preclinical testing. This news page aggregates these developments so readers can review clinical data readouts, conference participation, financing events, and regulatory and IP updates related to IMUX in one place.
Immunic (Nasdaq: IMUX) reported 2025 progress and near-term milestones for lead asset vidofludimus calcium and pipeline candidate IMU-856. Key achievements: completed enrollment in twin Phase 3 ENSURE trials (1,121 patients in ENSURE-1; 1,100 in ENSURE-2) with synchronized top-line data expected by end of 2026. Positive Phase 2 CALLIPER signals in progressive MS showed reductions in 24-week confirmed disability worsening and >2x probability of 24-week confirmed disability improvement. Long-term OLE EMPhASIS data showed 92.3% free of 12wCDW and 92.7% free of 24wCDW at week 144. USPTO notice allows patent protection into 2041. Company raised capital via $5.1M direct and $65M public offerings.
Immunic (Nasdaq: IMUX) announced that CEO Daniel Vitt, Ph.D. will participate in a fireside chat at the 8th Annual Evercore ISI Healthcare Conference on Thursday, December 4, 2025 at 9:35 am ET in Coral Gables, FL.
A webcast will be available in the Events and Presentations section of Immunic's investor website at https://ir.imux.com/events-and-presentations. Dr. Vitt and President/COO Jason Tardio will also hold one-on-one investor meetings during the conference; meeting requests can be made through Evercore ISI representatives or by contacting Jessica Breu at jessica.breu@imux.com.
Immunic (Nasdaq: IMUX) reported Q3 2025 results and clinical updates on November 13, 2025. Key clinical highlights include statistically significant 24-week confirmed disability improvement (24wCDI) from the phase 2 CALLIPER trial in progressive MS and supportive long-term EMPhASIS OLE data showing ~952 cumulative treatment years and an annualized discontinuation rate of ~6.4% up to 5.5 years.
The company received a U.S. patent allowance covering vidofludimus calcium dose strengths, expected to provide protection into 2041. Twin phase 3 ENSURE trials top-line data in relapsing MS are expected by year-end 2026.
Financials: Q3 net loss was ~$25.6M (Q3) and ~$77.9M (nine months); cash and equivalents were $35.1M with insufficient liquidity to fund operations for 12 months without additional capital.
Immunic (Nasdaq: IMUX) will participate in industry and investor conferences in November 2025. Company executives will attend BIO-Europe in Vienna on Nov 3–5, 2025 for partnering activities, with Daniel Vitt, Ph.D., Hella Kohlhof, Ph.D., and Jessica Breu representing the company.
Immunic executives will also host one-on-one meetings in London on Nov 19–20, 2025 in connection with the Jefferies Global Healthcare Conference—London; Daniel Vitt and Jason Tardio will attend. To schedule meetings, contact Jessica Breu via jessica.breu@imux.com or use the BIO-Europe partneringONE portal.
Immunic (NASDAQ: IMUX), a biotechnology company focused on inflammatory and autoimmune diseases, has announced its participation in several key scientific and investor conferences in October 2025. The company will present data on two key products: IMU-856, a SIRT6 modulator for celiac disease, at the United European Gastroenterology Week (UEGW), and vidofludimus calcium (IMU-838), a Nurr1 activator, at the International Society of Neuroimmunology Congress.
Management will also participate in investor-focused events, including Roth's 4th Annual Healthcare Opportunities Conference and a virtual fireside chat with H.C. Wainwright, providing opportunities for investor engagement and company updates.
Immunic (NASDAQ:IMUX) presented key data for vidofludimus calcium in multiple sclerosis at the 41st ECTRIMS Congress. The phase 2 CALLIPER trial demonstrated statistically significant results in progressive multiple sclerosis, showing over two-fold probability of 24-week confirmed disability improvement versus placebo.
The drug reduced the risk of 24-week confirmed disability worsening by 23.8% versus placebo in the overall population and by 33.7% in patients without gadolinium-enhancing lesions. Long-term data from the Phase 2 EMPhASIS trial in relapsing-remitting MS showed 92.3% of patients remained free of 12-week confirmed disability worsening at week 144, with favorable safety profiles.
Immunic (NASDAQ:IMUX) has received a Notice of Allowance from the USPTO for a patent application covering dose strengths of its lead asset vidofludimus calcium (IMU-838) for treating progressive multiple sclerosis (PMS). The patent specifically covers daily doses of 10-45mg for treating PMS, including primary and secondary progressive forms.
The patent provides protection until 2041 and follows positive phase 2 CALLIPER trial results where vidofludimus calcium demonstrated neuroprotective potential by delaying time to 24-week confirmed disability worsening (24wCDW). The drug also showed reductions in thalamic brain volume loss and volume of new/enlarging T2 lesions.
This is the fifth U.S. patent for vidofludimus calcium in multiple sclerosis, part of a multi-layered intellectual property strategy that includes patents for composition-of-matter, treatment methods, and dosing regimens.
Immunic (NASDAQ: IMUX), a biotechnology company focused on inflammatory and autoimmune diseases, has announced its participation in three major conferences in September 2025. The company will present at the H.C. Wainwright Global Investment Conference (Sept 8-10), attend the Leerink Partners Biopharma Summit (Sept 17-19), and participate in the 41st ECTRIMS Congress (Sept 24-26).
At ECTRIMS, the company will showcase significant data on its lead drug candidate vidofludimus calcium (IMU-838), featuring one oral presentation and four poster presentations. The presentations will focus on the drug's efficacy and safety in multiple sclerosis treatment, including results from the Phase 2 CALLIPER trial in progressive MS and long-term safety data from the EMPhASIS trial in relapsing-remitting MS.
Immunic (NASDAQ: IMUX) reported Q2 2025 financial results and significant progress in its clinical pipeline. The company's lead drug vidofludimus calcium showed promising results in multiple sclerosis trials, with a 23.8% reduction in disability worsening in progressive MS patients. Key highlights include completed enrollment for twin Phase 3 ENSURE trials in relapsing MS, with top-line data expected by end of 2026.
The company strengthened its financial position through two financings totaling $70.1 million in gross proceeds. Q2 2025 resulted in a net loss of $27.0 million ($0.20 per share), with cash position of $55.3 million as of June 30, 2025. However, current liquidity is insufficient to fund operations for the next twelve months without additional capital.
Immunic (NASDAQ:IMUX) has reported promising long-term data from the Phase 2 EMPhASIS trial's open-label extension (OLE) studying vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS) patients. At Week 144, the trial demonstrated remarkable results with 92.3% of patients remaining free of 12-week confirmed disability worsening (CDW) and 92.7% free of 24-week CDW.
The study, representing approximately 952 treatment years, showed that of 29 CDW events confirmed at 12 weeks, 44.8% were associated with relapse-associated worsening, while only 13.8% were linked to progression independent of relapse activity. The drug maintained a favorable safety profile with low discontinuation rates and no new safety signals emerging during treatment durations up to 5.5 years.
FAQ
What is the current stock price of Immunic (IMUX)?
What is the market cap of Immunic (IMUX)?
